On May 13, WuXi AppTec’s A-shares opened significantly higher at 48.51 yuan per share, an increase of 8.16%. However, after opening, the stock's gains narrowed, ultimately closing up 2.99% at 46.19 yuan per share. WuXi AppTec's H-shares in Hong Kong showed a similar trend, opening 14.96% higher but quickly declining, ending the day with a 4.46% gain. This market behavior was primarily influenced by developments regarding the U.S. Biodefense Act.

SOURCE：Investing
Data as of May 15,2024

Impact of the Biodefense Act on WuXi AppTec
The Biodefense Act is a proposed U.S. congressional bill aimed at enhancing national biosecurity. It recommends banning contracts with certain biotech suppliers, including WuXi AppTec, to prevent foreign biotech companies from accessing U.S. taxpayer funds. This bill could have significant implications for Chinese biotech companies like WuXi AppTec.

1.Restricted Collaborations: The act proposes prohibiting U.S. federal agencies from contracting with companies using equipment and services from certain "concerning biotech enterprises," directly impacting businesses like WuXi AppTec in the U.S.
2.Transition Period: The revised Biodefense Act, released by Congress, requires U.S. companies to end collaborations with some Chinese biotech research service providers, including WuXi AppTec, by January 2032, providing an approximately 8-year buffer period.
3.Market Reaction: Changes in the bill's provisions caused fluctuations in WuXi AppTec's stock price. On May 13, the stock opened with a gap up but saw gains narrow subsequently, reflecting the market's high attention to and uncertainty about the bill's progress.
4.Business Adjustments: WuXi AppTec and similar companies might need to reassess their U.S. business strategies and explore collaboration opportunities in other countries to reduce reliance on the U.S. market.
5.Industry Impact: The act affects the entire CRO (Contract Research Organization) industry, prompting the sector to consider diversified global supply chains and risk management strategies.

Fundamental Analysis of WuXi AppTec
WuXi AppTec, as a globally leading comprehensive pharmaceutical R&D service platform, boasts a highly qualified team of scientists and a stable customer base. The company provides end-to-end services, from drug discovery to commercial production, through its "CRDMO" and "CTDMO" business models. WuXi AppTec demonstrates robust financial performance, maintaining high levels of gross profit margin and return on equity (ROE).

SOURCE: First Financial

Future Growth Potential and Valuation
The outsourcing services market for pharmaceutical research and development is expected to have a compound annual growth rate of 13.6% over the next five years. With its leading position in the industry, WuXi AppTec is poised to continue benefiting from this growth. Based on financial forecasts, WuXi AppTec's net profit attributable to shareholders is estimated to be between 9.1 to 9.6 billion yuan in 2024. Considering the company's valuation analysis, under the current market capitalization, WuXi AppTec's stock presents a certain investment appeal.

SOURCE: WuXi AppTec financial reports

As a sector with long-term growth prospects, the pharmaceutical industry is driven by both policy support and market demand. Currently, developments in emerging fields like synthetic biology and stem cell therapy are presenting new growth opportunities for the industry. When considering investments in WuXi AppTec, investors should focus on its strategic positioning and research progress in these emerging fields, as well as the potential impact of policy changes on the company's business operations.

How to place a trade on uSMART mobile application：
Log in to the uSMART SG APP, click on the "Search" icon at the top right corner of the screen, and enter the stock code "02359",or the stock name"WUXI APPTEC" to access the details page for trading information and historical trends. Click the "Trade" button at the bottom right corner, select the "Buy/Sell" function, fill in the trading conditions, and submit the order. The visual guide is as follows:

This diagram is provided for illustrative purposes exclusively

Follow us

Find us on Twitter, Instagram, YouTube, and TikTok for frequent updates on all things investing.
Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！

Important Notice and Disclaimer:
We have based this article on our internal research and information available to the public from sources we believe to be reliable. While we have taken all reasonable care in preparing this article, we do not represent the information contained in this article is accurate or complete and we accept no responsibility for errors of fact or for any opinion expressed in this article. Opinions, projections and estimates reflect our assessments as of the article date and are subject to change. We have no obligation to notify you or anyone of any such change. You must make your own independent judgment with respect to any matter contained in this article. Neither we or our respective directors, officers or employees will be responsible for any losses or damages which any person may suffer or incur as a result of relying upon anything stated or omitted from this article.
This document should not be construed in any jurisdiction as constituting an offer, solicitation, recommendation, inducement, endorsement, opinion, or guarantee to purchase, sell, or trade any securities, financial products, or instruments or to engage in any investment or any transaction of any kind, nor is there any intention to solicit or invite the purchase or sale of any securities.
The value of these securities and the income from them may fall or rise. Your investment is subject to investment risk, including loss of income and capital invested. Past performance figures as well as any projection or forecast used in this article is not indicative of its future performance.
This advertisement has not been reviewed by the Monetary Authority of Singapore